FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Axel Haferkamp

Research Profile

Disorders

Concepts & Ideas

Procedures

Anatomy

Physiology

Urodynamics

Chemicals & Drugs

Biological Tumor Markers

Co-author Network

Publications

TOP 3
D Schilling; I Tsaur; Axel Haferkamp; M Kurosch; R Mager; M Röthke
[Fusion imaging in urology : Combination of MRI and TRUS for detection of prostate cancer].
Stefan Vallo; Georg Bartsch; Axel Haferkamp; Eva Juengel; Jasmina Makarević; Jens Mani; Matthias Stastny; Igor Tsaur; Roman A Blaheta
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Nina Wagener; I Karapanagiotou-Schenkel; S Macher-Goeppinger; S C Müller; Mona Abdel-Rahim; H Abol-Enein; P J Bastian; J Bulkescher; M A Ghoneim; Axel Haferkamp; G Hatiboglu; M Hohenfellner; Felix Hoppe-Seyler; K Hoppe-Seyler
Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Axel Haferkamp (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: D Schilling; I Tsaur; Axel Haferkamp; M Kurosch; R Mager; M Röthke
[Fusion imaging in urology : Combination of MRI and TRUS for detection of prostate cancer].
Der Urologe. Ausg. A 2013;52(4):481-9.
2013: Stefan Vallo; Georg Bartsch; Axel Haferkamp; Eva Juengel; Jasmina Makarević; Jens Mani; Matthias Stastny; Igor Tsaur; Roman A Blaheta
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Investigational new drugs 2013;31(2):265-72.
2013: Nina Wagener; I Karapanagiotou-Schenkel; S Macher-Goeppinger; S C Müller; Mona Abdel-Rahim; H Abol-Enein; P J Bastian; J Bulkescher; M A Ghoneim; Axel Haferkamp; G Hatiboglu; M Hohenfellner; Felix Hoppe-Seyler; K Hoppe-Seyler
Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients.
British journal of cancer 2013;108(4):973-82.
2013: Eva Juengel; Jasmina Makarević; Karen Nelson; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
PloS one 2013;8(1):e53100.
2012: Wolfgang Otto; Hubertus Riedmiller; Jan Roigas; Christian G Stief; Derya Tilki; Lutz Trojan; Wolf F Wieland; Mario Zacharias; Stefan Denzinger; Duska Dragun; Jörg Ellinger; Hans-Martin Fritsche; Michael Gierth; Christian Gilfrich; Axel Haferkamp; Edwin Herrmann; Thomas Höfner; Markus Hohenfellner; Arkadius Kocot; Matthias May; Rudolf Moritz; Stefan C Müller; Philipp Nuhn; Atiqullah Aziz; Patrick J Bastian; Sabine Brookman-May; Alexander Buchner; Maximilian Burger
Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder.
Gender medicine 2012;9(6):481-9.
2012: Lukasz Hudak; Eva Juengel; Jasmina Makarević; Patrick Tezeeh; Igor Tsaur; S Wedel; Christoph Wiesner; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
The Prostate 2012;72(16):1719-35.
2012: Eva Juengel; Jasmina Makarević; Igor Tsaur; Christoph Wiesner; Georg Bartsch; Anna Dauselt; Axel Haferkamp; Roman A Blaheta
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
Cancer letters 2012;324(1):83-90.
2012: I Tsaur; Ana Maria Waaga-Gasser; S Wedel; C Wiesner; Martin Gasser; Axel Haferkamp; E Juengel; M Kurosch; J Makarević; M Reiter; G Bartsch; Roman A Blaheta
Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.
British journal of cancer 2012;107(5):847-55.
2012: Matthias May; Stefan C Müller; Philipp Nuhn; Wolfgang Otto; Jan Roigas; Christian G Stief; Derya Tilki; Lutz Trojan; Wolf F Wieland; Mario Zacharias; Patrick J Bastian; Christian Bolenz; Sabine Brookman-May; Alexander Buchner; Jörg Ellinger; Hans-Martin Fritsche; Christian Gilfrich; Axel Haferkamp; Edwin Herrmann; Markus Hohenfellner; Maximilian Burger
External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder.
The Journal of urology 2012;187(4):1210-4.
2012: Thomas Hofner; Sascha Pahernik; Jesco Pfitzenmaier; Nina Wagener; Adel Alrabadi; Nenad Djakovic; Boris A Hadaschik; Axel Haferkamp; Markus Hohenfellner
PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy.
World journal of urology 2012;30(1):91-5.
2012: Jens Mani; Karen Nelson; Hanns Ackermann; Axel Haferkamp; Eva Juengel; Jasmina Makarević; Roman A Blaheta
Publication of original research in urologic journals--a neglected orphan?
PloS one 2012;7(12):e52420.
2012: Sascha A Müller; Sascha Pahernik; Moritz N Wente; Markus W Büchler; Thilo Hackert; Axel Haferkamp; Ulf Hinz; Christine Leowardi; David J Martin; Bruno M Schmied
Renal tumors and second primary pancreatic tumors: a relationship with clinical impact?
Patient safety in surgery 2012;6(1):18.
2011: Igor Tsaur; Christoph Wiesner; Georg Bartsch; Axel Haferkamp; Sebastian Harder; Lukasz Hudak; Eva Juengel; M Kurosch; Jasmina Makarević; Roman A Blaheta
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.
Cancer letters 2011;313(1):84-90.
2011: Sascha Pahernik; Jesco Pfitzenmaier; Axel Haferkamp; Johannes Huber; Markus Hohenfellner
Small renal cell carcinoma: oncological outcome with tumour size.
Scandinavian journal of urology and nephrology 2011;45(6):432-5.
2011: Gencay Hatiboglu; Axel Haferkamp; Johannes Huber; M Kurosch; Sascha Pahernik; Jesco Pfitzenmaier; Valentin Popeneciu; Markus Hohenfellner
Prognostic variables for shockwave lithotripsy (SWL) treatment success: no impact of body mass index (BMI) using a third generation lithotripter.
BJU international 2011;108(7):1192-7.
2011: Sascha Pahernik; Michael Reiter; Gencay Hatiboglu; Johannes Huber; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Combining open and laparoscopic surgery for partial nephrectomy.
Journal of endourology / Endourological Society 2011;25(5):821-4.
2011: Johannes Huber; Sascha Pahernik; Peter Hallscheidt; Christof M Sommer; Nina Wagener; Gencay Hatiboglu; Axel Haferkamp; Markus Hohenfellner
Selective transarterial embolization for posttraumatic renal hemorrhage: a second try is worthwhile.
The Journal of urology 2011;185(5):1751-5.
2011: Stephan Macher-Goeppinger; Justo Lorenzo Bermejo; Nina Wagener; Markus Hohenfellner; Axel Haferkamp; Peter Schirmacher; Wilfried Roth
Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas.
Cancer letters 2011;301(2):203-11.
2011: Igor Tsaur; Ana Maria Waaga-Gasser; S Wedel; Christoph Wiesner; Hanns Ackermann; Georg Bartsch; Martin Gasser; Axel Haferkamp; Tanja Huesch; M Kurosch; Maria Lazariotou; Jasmina Makarevic; Anika Noack; Elsie Oppermann; Lars Schmitt; Roman A Blaheta
Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer.
Cancer biomarkers : section A of Disease markers 2011;10(5):195-204.
2011: Thomas Hofner; Axel Haferkamp; Lena Knapp; Sascha Pahernik; Boris Hadaschik; Nenad Djakovic; Nina Wagener; Markus Hohenfellner
Preoperative hydronephrosis predicts advanced bladder cancer but is not an independent factor for cancer-specific survival after radical cystectomy.
Urologia internationalis 2011;86(1):25-30.
2010: Johannes Huber; Sascha Pahernik; Peter Hallscheidt; Christof Matthias Sommer; Gencay Hatiboglu; Axel Haferkamp; Markus Hohenfellner
Risk factors and clinical management of haemorrhage after open nephron-sparing surgery.
BJU international 2010;106(10):1488-93.
2010: J N Nyarangi-Dix; D Schultz-Lampel; U Hohenfellner; J Huber; G Hatiboglu; N Djakovic; Axel Haferkamp; Markus Hohenfellner
[Conservative management of postoperative urinary incontinence in men].
Der Urologe. Ausg. A 2010;49(4):498-503.
2010: J Huber; Peter Hallscheidt; Nina Wagener; Sascha Pahernik; Axel Haferkamp; Markus Hohenfellner
[Tumours of the Kidney: CT vs. MRI. Nearly equal alternatives with minor differences].
Der Urologe. Ausg. A 2010;49(3):345-50.
2010: Axel Haferkamp; M Kurosch; Maria Pritsch; Gencay Hatiboglu; Stephan Macher-Goeppinger; Jesco Pfitzenmaier; Sascha Pahernik; Nina Wagener; Markus Hohenfellner
Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications.
Annals of surgical oncology 2010;17(2):544-51.
2010: Nina Wagener; Stephan Macher-Goeppinger; Maria Pritsch; Johannes Hüsing; Karin Hoppe-Seyler; Peter Schirmacher; Jesco Pfitzenmaier; Axel Haferkamp; Felix Hoppe-Seyler; Markus Hohenfellner
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
BMC cancer 2010;10():524.
2009: Jesco Pfitzenmaier; Sascha Pahernik; Stephan Buse; Axel Haferkamp; Nenad Djakovic; Markus Hohenfellner
Survival in prostate cancer patients > or = 70 years after radical prostatectomy and comparison to younger patients.
World journal of urology 2009;27(5):637-42.
2009: Stephan Buse; Jesco Pfitzenmaier; Nina Wagener; Axel Haferkamp; Markus Hohenfellner
Functional results 1 year after laser vaporization of the prostate: the impact of age.
Journal of endourology / Endourological Society 2009;23(8):1339-42.
2009: M A Reiter; Jesco Pfitzenmaier; Markus Hohenfellner; Axel Haferkamp
[Immunomodulatory treatment approaches for prostate cancer].
Der Urologe. Ausg. A 2009;48(7):755-63.
2009: Stephan Buse; Christian Gilfrich; Gencay Hatiboglu; Johannes Huber; Jens Bedke; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate.
World journal of urology 2009;27(3):405-9.
2009: Nenad Djakovic; Nina Wagener; Judith Adams; Christian Gilfrich; Axel Haferkamp; Jesco Pfitzenmaier; Burkhard Toenshoff; Jan Schmidt; Markus Hohenfellner
Intestinal reconstruction of the lower urinary tract as a prerequisite for renal transplantation.
BJU international 2009;103(11):1555-60.
2009: J N Nyarangi-Dix; N Djakovic; M Kurosch; Axel Haferkamp; Markus Hohenfellner
[Reconstructive pelvic surgery. Current status and future perspectives].
Der Urologe. Ausg. A 2009;48(5):510-5.
2009: Jens Bedke; Stephan Buse; Maria Pritsch; Stephan Macher-Goeppinger; Peter Schirmacher; Axel Haferkamp; Markus Hohenfellner
Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences.
BJU international 2009;103(10):1349-54.
2009: Jesco Pfitzenmaier; Maria Pritsch; Axel Haferkamp; Hildegard Jakobi; Frederik Fritsch; Christian Gilfrich; Nenad Djakovic; Stephan Buse; Sascha Pahernik; Markus Hohenfellner
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
BJU international 2009;103(7):877-82.
2009: Stephan Macher-Goeppinger; Sebastian Aulmann; Katrin E Tagscherer; Nina Wagener; Axel Haferkamp; Roland Penzel; Antje Brauckhoff; Markus Hohenfellner; Jaromir Sykora; Henning Walczak; Bin Tean Teh; Frank Autschbach; Esther Herpel; Peter Schirmacher; Wilfried Roth
Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):650-9.
2008: Axel Haferkamp; Jens Bedke; Caroline Vetter; Maria Pritsch; Nina Wagener; Stephan Buse; Irena Crnkovic-Mertens; Karin Hoppe-Seyler; Stephan Macher-Goeppinger; Felix Hoppe-Seyler; Frank Autschbach; Markus Hohenfellner
High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma.
BJU international 2008;102(11):1700-6.
2008: Jesco Pfitzenmaier; Sascha Pahernik; Tina Tremmel; Axel Haferkamp; Stephan Buse; Markus Hohenfellner
Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
BJU international 2008;102(10):1413-8.
2008: Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Decoy receptor 3 is a prognostic factor in renal cell cancer.
Neoplasia (New York, N.Y.) 2008;10(10):1049-56.
2008: Nina Wagener; Daniela Holland; Julia Bulkescher; Irena Crnković-Mertens; Karin Hoppe-Seyler; Hanswalter Zentgraf; Maria Pritsch; Stephan Buse; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner; Felix Hoppe-Seyler
The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
International journal of cancer. Journal international du cancer 2008;123(7):1545-50.
2008: Jesco Pfitzenmaier; Christian Gilfrich; Maria Pritsch; Daniela Herrmann; Stephan Buse; Axel Haferkamp; Nenad Djakovic; Sascha Pahernik; Markus Hohenfellner
Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL.
BJU international 2008;102(3):322-7.
2008: Jens Bedke; Maria Pritsch; Stephan Buse; Hildegard Jakobi; Karl-Heinz Elsaesser; Sascha Pahernik; Axel Haferkamp; Markus Hohenfellner
Prognostic stratification of localized renal cell carcinoma by tumor size.
The Journal of urology 2008;180(1):62-7.
2008: Jesco Pfitzenmaier; Christian Gilfrich; Axel Haferkamp; Stephan Buse; Markus Hohenfellner
Change of ureteral submucosal anti-reflux implantation into an intussuscepted ileal nipple valve as reflux protection in ureterosigmoidostomy.
Urology 2008;72(1):192-5.
2008: S Macher-Goeppinger; Sebastian Aulmann; Axel Haferkamp; Markus Hohenfellner; Peter Schirmacher; Hendrik Bläker
[Villous adenoma within an urachal diverticulum associated with long-term mucusuria].
Der Pathologe 2008;29(4):305-7.
2008: Axel Haferkamp
Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
European urology 2008;53(6):1253.
2008: Axel Haferkamp; Maria Pritsch; Jens Bedke; Nina Wagener; Jesco Pfitzenmaier; Stephan Buse; Markus Hohenfellner
The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy.
BJU international 2008;101(10):1243-6.
2008: Jens Rassweiler; Peter Prager; Axel Haferkamp; Peter Alken; Günther W Kauffmann; Götz Richter
Transarterial nephrectomy: the current status of experimental and clinical studies.
Journal of endourology / Endourological Society 2008;22(4):767-82.
2008: Stephan Buse; Christian Gilfrich; Jesco Pfitzenmaier; Jens Bedke; Axel Haferkamp; Markus Hohenfellner
En bloc stapler ligation of the renal vascular pedicle during laparoscopic nephrectomy.
BJU international 2008;101(7):878-82.
2007: Stefan Hauser; C Fisang; F Fechner; Jörg Ellinger; Axel Haferkamp; Stefan C Müller
[Ureterocystoplasty in the treatment of "low-compliance" bladder in children].
Der Urologe. Ausg. A 2007;46(12):1687-90.
2007: Nina Wagener; I Crnković-Mertens; C Vetter; S Macher-Göppinger; Jens Bedke; Elisabeth F Gröne; Hanswalter Zentgraf; Maria Pritsch; K Hoppe-Seyler; Stephan Buse; Axel Haferkamp; F Autschbach; Markus Hohenfellner; Felix Hoppe-Seyler
Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney.
British journal of cancer 2007;97(9):1271-6.
2007: Nenad Djakovic; Axel Haferkamp; Markus Hohenfellner
[Hypospadias].
Der Urologe. Ausg. A 2007;46(9):1047-53.
2007: Axel Haferkamp; M Hohenfellner; Richard Hautmann; Margot Zöller
[Renal cell carcinoma associated proteins. Isolation, cloning and immunogenicity evaluation].
Der Urologe. Ausg. A 2007;46(9):1292-8.
2007: Michael Akbar; Rainer Abel; Thorsten M Seyler; Jens Bedke; Axel Haferkamp; Hans Jürgen Gerner; Klaus Möhring
Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
BJU international 2007;100(3):639-45.
2007: Axel Haferkamp; Nenad Djakovic
Editorial comment on: Urethral reconstruction using the radial forearm free flap: experience in oncologic cases and gender reassignment.
European urology 2007;52(2):554.
2007: Axel Haferkamp; Patrick J Bastian; Hildegard Jakobi; Maria Pritsch; Jesco Pfitzenmaier; Peter Albers; Peter Hallscheidt; Stefan C Müller; Markus Hohenfellner
Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
The Journal of urology 2007;177(5):1703-8.
2007: I Crnković-Mertens; Nina Wagener; Julia Semzow; Elisabeth F Gröne; Axel Haferkamp; Markus Hohenfellner; Karin Butz; Felix Hoppe-Seyler
Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis.
Cellular and molecular life sciences : CMLS 2007;64(9):1137-44.
2007: Stephan Buse; André Reitz; Axel Haferkamp; Markus Hohenfellner
[Conservative treatment of male stress incontinence].
Der Urologe. Ausg. A 2007;46(3):240-3.
2007: Judith Adams; Nenad Djakovic; Christian Gilfrich; Jesco Pfitzenmaier; Stephan Buse; Axel Haferkamp; Markus Hohenfellner
Ureteric replacement with Meckel's diverticulum.
BJU international 2007;99(3):647-50.
2007: Chengwen Zhang; Till Wenger; Jürgen Mattern; Septimia Ilea; Christian R Frey; Paul Gutwein; Peter Altevogt; Wolfram Bodenmüller; Nikolaus Gassler; Philipp A Schnabel; Hendrik Dienemann; Alexander Marmé; Markus Hohenfellner; Axel Haferkamp; Jesco Pfitzenmaier; Hermann-Josef Gröne; Armin Kolb; Peter Büchler; Markus Büchler; Helmut Friess; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; Peter H Krammer; Hans Peter Rutz; Ingrid Herr
Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors.
Cancer biology & therapy 2007;6(2):278-87.
2007: Elisabeth Sievers; Patrick Dreimuller; Axel Haferkamp; Ingo G H Schmidt-Wolf; Markus W Buchler; Jan Schmidt; Angela Marten
Characterization of primary renal carcinoma cultures.
Urologia internationalis 2007;79(3):235-43.
2007: Stephan Buse; Jens Bedke; M Kurosch; Axel Haferkamp; Andreas Unterberg; Klaus K Herfarth; Markus Hohenfellner
[Brain metastases in cases of renal cell carcinoma].
Der Urologe. Ausg. A 2007;46(1):36-9.
2007: M Kurosch; Stephan Buse; Jens Bedke; Nina Wagener; Axel Haferkamp; Markus Hohenfellner
[Palliative and supportive therapy in cases of renal cell carcinoma].
Der Urologe. Ausg. A 2007;46(1):40-4.
2007: Jens Bedke; Stephan Buse; M Kurosch; Axel Haferkamp; D Jäger; Markus Hohenfellner
[Paraneoplastic syndrome in renal cell carcinoma].
Der Urologe. Ausg. A 2007;46(1):45-8.
2006: Peter Hallscheidt; Nina Wagener; Farshad Gholipour; Nastaran Aghabozorgi; Jens Dreyhaupt; Markus Hohenfellner; Axel Haferkamp; Jesco Pfitzenmaier
Multislice computed tomography in planning nephron-sparing surgery in a prospective study with 76 patients: comparison of radiological and histopathological findings in the infiltration of renal structures.
Journal of computer assisted tomography 2006;30(6):869-74.
2006: Stephan Buse; Christian Gilfrich; Nina Wagener; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Thoraco-abdominal approach to large retroperitoneal tumours.
BJU international 2006;98(5):969-72.
2006: Axel Haferkamp; Markus Hohenfellner
[Intravesical treatment of overactive bladder syndrome].
Der Urologe. Ausg. A 2006;45(10):1283-8.
2006: J N Nyarangi-Dix; Axel Haferkamp; André Reitz; Markus Hohenfellner
[Overactive bladder syndrome. Are there indications for surgical therapy?].
Der Urologe. Ausg. A 2006;45(10):1289-90, 1292.
2006: Sönke Boy; André Reitz; Barbara Wirth; Peter A Knapp; Peter M Braun; Axel Haferkamp; Brigitte Schurch
Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women.
European urology 2006;50(1):119-25.
2006: Nikolaus Gassler; Axel Haferkamp; Christa Flechtenmacher; Markus Hohenfellner; Peter Schirmacher; Frank Autschbach
[Renal oncocytoma with metastasis from breast carcinoma: a contribution to the differential diagnosis of tumourous lesions of the kidney].
Der Pathologe 2006;27(3):217-21.
2006: Gerard Devitt; Christiane Meyer; Nicole Wiedemann; Stefan B Eichmüller; Annette Kopp-Schneider; Axel Haferkamp; Richard Hautmann; Margot Zöller
Serological analysis of human renal cell carcinoma.
International journal of cancer. Journal international du cancer 2006;118(9):2210-9.
2006: Peter Hallscheidt; S Besharati; Gerd Noeldge; Axel Haferkamp; R Lopez; Günter W Kauffmann
[Preoperative and palliative embolization of renal cell carcinomas: follow-up of 49 patients].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2006;178(4):391-9.
2006: Julia S Schleypen; Nicole Baur; Robert Kammerer; Peter J Nelson; Karl Rohrmann; Elisabeth F Gröne; Markus Hohenfellner; Axel Haferkamp; Heike Pohla; Dolores Schendel; Christine S Falk; Elfriede Noessner
Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):718-25.
2006: Axel Haferkamp; Thomas Freund; Nina Wagener; André Reitz; Brigitte Schurch; Joachim Doersam; Stefan Schumacher; Patrick J Bastian; Reinold J Buettner; Stefan C Mueller; Markus Hohenfellner
Distribution of neuropeptide Y-containing nerves in the neurogenic and non-neurogenic detrusor.
BJU international 2006;97(2):393-9.
2006: André Reitz; Axel Haferkamp; Nina Wagener; Hans Jürgen Gerner; Markus Hohenfellner
Neurogenic bladder dysfunction in patients with neoplastic spinal cord compression: adaptation of the bladder management strategy to the underlying disease.
NeuroRehabilitation 2006;21(1):65-9.
2006: Chengwen Zhang; Jürgen Mattern; Axel Haferkamp; Jesco Pfitzenmaier; Markus Hohenfellner; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; E Groene; Ingrid Herr
Corticosteroid-induced chemotherapy resistance in urological cancers.
Cancer biology & therapy 2006;5(1):59-64.
2005: André Reitz; Axel Haferkamp; Markus Hohenfellner
[Afferent pathways arising from the lower urinary tract. Physiology, pathophysiology, and clinical implications].
Der Urologe. Ausg. A 2005;44(12):1452-7.
2005: Nina Wagener; André Reitz; Jesco Pfitzenmaier; Jürgen Pannek; Patrick J Bastian; Reinhard Büttner; Stefan C Müller; Markus Hohenfellner; Axel Haferkamp
Adherens junctions of the human detrusor.
BJU international 2005;96(6):843-7.
2005: André Reitz; Michael Müntener; Axel Haferkamp; Markus Hohenfellner; Brigitte Schurch
Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?
BJU international 2005;96(3):250-3.
2005: Patrick J Bastian; Axel Haferkamp; I Akbarov; P Albers; S C Müller
Surgical outcome following radical nephrectomy in cases with inferior vena cava tumour thrombus extension.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(4):420-3.
2005: Axel Haferkamp; Nina Wagener; Stephan Buse; André Reitz; Jesco Pfitzenmaier; Peter Hallscheidt; Markus Hohenfellner
[Vesicovaginal fistulas].
Der Urologe. Ausg. A 2005;44(3):270-6.
2005: Peter Hallscheidt; Christian Fink; Axel Haferkamp; Michael Bock; Ante Luburic; Ivan Zuna; Gerd Noeldge; Günter W Kauffmann
Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation.
Journal of computer assisted tomography 2005;29(1):64-8.
2004: Axel Haferkamp; J Mundhenk; Patrick J Bastian; André Reitz; Joachim Dörsam; Jürgen Pannek; Stefan Schumacher; Brigitte Schurch; R Büttner; Stefan C Müller
Increased expression of connexin 43 in the overactive neurogenic detrusor.
European urology 2004;46(6):799-805.
2004: Axel Haferkamp; Brigitte Schurch; André Reitz; U Krengel; Joachim Grosse; Guus Kramer; Stefan Schumacher; Patrick J Bastian; R Büttner; Stefan C Müller; Manfred Stöhrer
Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
European urology 2004;46(6):784-91.
2004: Patrick J Bastian; Peter Albers; Herbert Hanitzsch; Giancarlo Fabrizi; Romano Casadei; Axel Haferkamp; Stefan Schumacher; Stefan C Müller
Health-related quality-of-life following modified ureterosigmoidostomy (Mainz Pouch II) as continent urinary diversion.
European urology 2004;46(5):591-7.
2004: Patrick J Bastian; Peter Albers; Axel Haferkamp; Stefan Schumacher; Stefan C Müller
Modified ureterosigmoidostomy (Mainz Pouch II) in different age groups and with different techniques of ureteric implantation.
BJU international 2004;94(3):345-9.
2004: André Reitz; Axel Haferkamp; Tatiana Kyburz; Peter A Knapp; Björn Wefer; Brigitte Schurch
The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women.
European urology 2004;46(2):235-40; discussion 240.
2004: Patrick J Bastian; Peter Albers; H Hanitzsch; G Fabrizi; R Casadei; Axel Haferkamp; Stefan Schumacher; Stefan C Müller
[The modified ureterosigmoidostomy (Mainz pouch II) as a continent form of urinary diversion].
Der Urologe. Ausg. A 2004;43(8):982-8.
2004: Axel Haferkamp; Ahmad Elbadawi
[Ultrastructural changes in the aging bladder].
Der Urologe. Ausg. A 2004;43(5):527-34.
2003: Stefan Schumacher; Axel Haferkamp; Stefan C Müller
[Bladder dysfunction due to rare neurological disorders].
Der Urologe. Ausg. A 2003;42(12):1564-8.
2003: Patrick J Bastian; Axel Haferkamp; Peter Albers; Stefan C Müller
[Medizip surgical zipper: a new form of non-invasive wound closure with a surgical zipper].
Aktuelle Urologie 2003;34(6):398-401.
2003: Axel Haferkamp; Diethild Melchior; Stefan Schumacher; Stefan C Müller
[Ureterocystoplasty: functional results and possible problem areas].
Der Urologe. Ausg. A 2003;42(7):954-9.
2003: Patrick J Bastian; Axel Haferkamp; Peter Albers; Stefan C Müller
A new form of noninvasive wound closure with a surgical zipper.
The Journal of urology 2003;169(5):1785-6.
2003: Axel Haferkamp; Joachim Dörsam; Neil M Resnick; Subbarao V Yalla; Ahmad Elbadawi
Structural basis of neurogenic bladder dysfunction. III. Intrinsic detrusor innervation.
The Journal of urology 2003;169(2):555-62.
2003: Axel Haferkamp; Joachim Dörsam; Neil M Resnick; Subbarao V Yalla; Ahmad Elbadawi
Structural basis of neurogenic bladder dysfunction. II. Myogenic basis of detrusor hyperreflexia.
The Journal of urology 2003;169(2):547-54.
2003: Ahmad Elbadawi; Neil M Resnick; Joachim Dörsam; Subbarao V Yalla; Axel Haferkamp
Structural basis of neurogenic bladder dysfunction. I. Methods of prospective ultrastructural study and overview of the findings.
The Journal of urology 2003;169(2):540-6.
2003: Axel Haferkamp; Joachim Dörsam; Ahmad Elbadawi
Ultrastructural diagnosis of neuropathic detrusor overactivity: validation of a common myogenic mechanism.
Advances in experimental medicine and biology 2003;539(Pt A):281-91.
2002: Axel Haferkamp; G Steiner; Stefan C Müller; Stefan Schumacher
Urethral erosion of tension-free vaginal tape.
The Journal of urology 2002;167(1):250.
2000: Axel Haferkamp; Klaus Möhring; Gerd Staehler; Joachim Dörsam
Pitfalls of repeat subureteral bovine collagen injections for the endoscopic treatment of vesicoureteral reflux.
The Journal of urology 2000;163(6):1919-21.
2000: Axel Haferkamp; Joachim Dörsam
Re: use of polydimethylsiloxane for endoscopic treatment of neurogenic urinary incontinence in children.
The Journal of urology 2000;163(6):1891-2.
2000: Axel Haferkamp; H Contractor; Klaus Möhring; Gerd Staehler; Joachim Dörsam
Failure of subureteral bovine collagen injection for the endoscopic treatment of primary vesicoureteral reflux in long-term follow-up.
Urology 2000;55(5):759-63.
2000: Axel Haferkamp; Gerd Staehler; Hans Jürgen Gerner; Joachim Dörsam
Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Spinal cord 2000;38(4):250-4.
2000: Axel Haferkamp; Klaus Möhring; Gerd Staehler; Hans Jürgen Gerner; Joachim Dörsam
Long-term efficacy of subureteral collagen injection for endoscopic treatment of vesicoureteral reflux in neurogenic bladder cases.
The Journal of urology 2000;163(1):274-7.
1999: Axel Haferkamp; Joachim Dörsam; Klaus Möhring; Manfred Wiesel; Gerd Staehler
Ureteral complications in renal transplantation with more than one donor ureter.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(6):1521-4.
1999: Axel Haferkamp; Drasko Brkovic; Manfred Wiesel; Gerd Staehler; Joachim Dörsam
Role of color-coded Doppler sonography in the assessment of internal ureteral stent patency.
Journal of endourology / Endourological Society 1999;13(3):199-203.